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Abstract
Background: There is no information about HRQoL, depression and associated factors in adult with nephrotic syndrome-
associated glomerulopathy.
Methodology/Principal Findings: Patients with primary glomerulopathy where compared with age and sex-matched
hemodialysis patients and healthy subjects. Laboratory data, medical history, comorbid conditions were collected to
evaluate factors associated with HRQoL (SF-36) and Depression (Hamilton Depression Rating Scale - HAMD).
Glomerulopathy patients had low HRQoL in all eight SF-36 domains and two composite scores (physical and mental) in
comparison with healthy subjects. HAMD score also was elevated and there was high depression prevalence. Overall, these
data were comparable between glomerulopathy and hemodialysis patients. Using multiple regression analysis, factors
associated with low HRQoL physical composite score were: last 24 h-urine protein excretion (20.183, 95%CI 20.223 to
20.710 for each gram of proteinuria, p=0.01) and cyclosporine use (215.315, 95%CI 225.913 to 22.717, p=0.03). Low
HRQoL mental composite score was associated with last 24 h-urine protein excretion (20.157, 95%CI 20.278 to 20.310 for
each gram of proteinuria, p=0.03) and HMAD score was independently associated with age (0.155, 95%CI 0.318 to 0.988 for
each year, p=0.04), female sex (4.788, 95%CI 1.005 to 8.620, 0=0.03), disease duration (0.074, 95%CI 0.021 to 0.128 for each
month, p=0.01) and last 24 h-urine protein excretion (0.050, 95%CI 0.018 to 0.085 for each gram of proteinuria, p=0.02).
Conclusions/Significance: Nephrotic-syndrome associated glomerulopathy patients have low HRQoL and high prevalence
of depression symptoms, comparable with those of hemodialysis patients. Last 24 h-protein excretion rate is independently
associated with physical and mental HRQoL domains in addition to depression.
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Introduction
Glomerulopathy is a group of diseases that affect mainly young
adults between 20–40 years old [1]. Patients with nephrotic
syndrome generally present with important edema, lipid alter-
ations, hypoalbuminemia, and possible loss of renal function.
Moreover, treatment involves dietary restrictions and immuno-
suppression therapy with their adverse effects. All these factors can
potentially affect health-related quality of life (HRQoL). Many
nephrotic syndrome features are related to a worse HRQoL:
protein-nutrition alteration [2], lipid metabolism alteration [3] and
reduced glomerular filtration rate (GRF) [4].
Depression is common in general medical patients, with female
prevalence of 5 to 9% and 2 to 3% in men [5]. Depression is
thought to be associated with worse general health status [6] and is
associated with several chronic diseases [7,8], including chronic
Kidney disease (CKD) [9]. In some populations, screening in some
special population, such as those undergoing renal replacement
therapy, is warranted given its high prevalence and association
with increased mortality and morbidity [10]. A close relationship
between HRQoL and depression has been well established [11].
Although, it is already well known that CKD is associated with a
decreased HRQoL, especially in dialysis populations [4,12,13],
only recently, adult patients with glomerular disease were studied
regarding their HRQoL [14]. Gipson et al. described these
patients had a low HRQoL, comparable with dialysis patients
[14]. However, this study population was a mix of children and
adults with the same glomerular pathology (focal segmental
glomerulosclerosis - FSGS) and they were studied at baseline
during a therapeutic randomized trial. It was not possible to
extrapolate the conclusions to other primary glomerulopathies and
there is no information on treatment effects and factors associated
with low HRQoL. Moreover, to the best of our knowledge, there is
no data about depression in adult glomerulopathy patients.
The objective of the present study is to evaluate HRQoL and
depression in a cohort of patients with a diagnosis of nephrotic
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37763syndrome-related primary glomerulopathy not undergoing chron-
ic renal replacement therapy.
Methods
This is a cross-sectional study with patients presenting nephrotic
syndrome at the time of a kidney biopsy in a reference university
hospital of Brazil (Hospital Geral de Fortaleza). Nephrotic
syndrome was defined as 24 h-urine protein greater than 3.5 g/
1.73 m
2 associated with edema, hypoalbuminemia (less than
3.0 g/dL) and lipid alteration. Only patients presenting primary
minimal lesions (ML), FSGS, Membranous Nephropathy (MN),
IgA nephropathy (IgAN) and membranoproliferative glomerulo-
nephritis (MPGN) at kidney biopsy were considered. Patients with
any evidence of secondary glomerulopathy or advanced CKD
(GFR less than 15 mL/min/1.73 m
2) were excluded.
Two age and sex-matched controls groups were selected: one
consisting of patients undergoing maintenance hemodialysis for
more than three months with no primary glomerulopathy
diagnosis and another with healthy subjects. The study protocol
was reviewed and approved by the Ethical Committee of the
Institution (University of Fortaleza – UNIFOR) and informed
consent was obtained from participants.
Measurements
Subjects underwent structured interviews during a research
clinic visit. The interviews were used to obtain patient symptom
checklist, medical comorbidities, sociodemographic characteristics,
HRQoL and depression assessment. The Short Form-36 (SF-36)
questionnaire was applied in the Portuguese version validated in
Brazil [15]. This scale covers eight domains, four physical and four
emotional ones. Each domain has a scale of 0 to 100, with a higher
score always representing better HRQoL. These scales are
aggregated into a physical composite score (PCS) and a mental
composite score (MCS).
Depression was evaluated by the 17-item Hamilton depression
Rating Scale (HAMD) also validated in Brazil [16]. The
questionnaire was administered according to the Interview Guide
for the Hamilton Rating Scale, of which purpose is to standardize
the questions. The questionnaire has a scale that classifies degrees
of depression according to these criteria: score lower than 6 –
without mood swings/normal; from 7 to 17 – slightly depressed;
from 18 to 24 – moderately depressed; above 25 – seriously
depressed.
Treatment Protocol Summary
All patients were treated with angiotensin-converting enzyme
inhibitors (ACE inhibitor) or AT1- receptor blocker (AT1R-
blocker) when there was no contraindication. In ML and FSGS,
the primary treatment was steroid-based therapy and cyclosporine
(CsA) when it was steroid-resistant or dependent. MN was treated
primarily with CsA or steroids plus cyclophosphamide according
to baseline renal function. IgAN presenting with nephrotic
syndrome was treated preferentially with steroids and MPGN
patients received no immunosuppressive treatment.
Laboratory Data and Definitions
Medical records were retrieved to assess laboratory data at the
kidney biopsy time and the last evaluation prior to study inclusion.
Laboratory data included an assessment of serum creatinine, total
blood count, serum albumin, total cholesterol, LDL cholesterol,
HDL cholesterol, triglycerides, 24 h-urine protein excretion rate
(24 h-proteinuria) and urinalysis. Immunosuppressive treatment
was considered only when it was taken for at least one month.
Edema was considered when it was present in the last clinical
evaluation. Hypertension was defined as blood pressure above
140690 mmHg at three or more medical evaluation or a positive
high blood pressure history under regular treatment. Hematuria
was considered as more than five red blood cells per high-power
microscopic field in two urine samples. Total remission was
considered when 24 h-proteinuria was less than 500 mg and
partial remission when there was a reduction greater than 50% of
initial 24 h-proteinuria and it was less than 3.5 g/24 h/1.73 m
2.
Relapses were considered in patients presenting with 24 h-
proteinuria greater than 3.5 g/24 h/1.73 m
2 and serum albumin
less than 3.0 g/dL after achieving partial or total remission.
Table 1. Patients’ clinical and demographic characteristics.
Data are presented as mean6SD or absolute values.
Glomerulopathy patients
(n=99)
Age (years) 36611
Gender (M/F) 46/53
Renal biopsy diagnosis
FSGS 49
MN 29
IgAN 9
MPGN 8
ML 4
Disease duration (months) 33.6626.0
Arterial Hypertension 40
Diabetes 6
Familial nephropathy history 21
Presence of edema 31
Mean eGFR (mL/min/1.73 m
2)6 1 629
CKD stage
stage 1 55
stage 2 24
stage 3 16
stage 4 04
ACE inhibitor/AT1R blocker 62
Steroid therapy 43
Cyclosporine therapy 19
Cyclophosphamide therapy 03
Hemoglobin (g/dL) 12.360.9
Last serum albumin (g/dL) 3.660.9
Last total cholesterol (mg/dL) 221698
Last triglycerides (mg/dL) 146658
Proteinuria at diagnosis (g/24 h/1.73 m
2) 8.663.8
Last proteinuria (g/24 h/1.73 m
2) 2.862.2
Remission
Total 38
Parcial 26
No 35
FSGS: focal and segmentar glomerulosclerosis; ML: minimal lesions; MN:
membranous Nephropathy; IgAN: IgA nephropathy; MPGN:
membranoproliferative Glomerulonephritis; CKD: Chronic Kidney Disease; ACE:
angiotensin converting enzyme; AT1R: angiotensin 1 receptor.
doi:10.1371/journal.pone.0037763.t001
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Quality of Life and Depression in GlomerulopathyFrequent relapses were considered when there was more than 2
relapses in six months or 3 in a year. Estimated GFR (eGFR) was
calculated using simplified MDRD equation. The local ethic’s
committee approved the study.
Statistical Analysis
Descriptive statistics are expressed as mean6SD or absolute
numbers as appropriate. All variables were tested for normal
distribution using the Kolmogorov-Smirnov test. One-way
ANOVA with Bonferroni post-test or student’s t-test was applied
to compare means of continuous variables and normal distribution
data. Categorical data were tested using the chi-square test.
Continuous estimated predictors of PCS, MCS and HAMD
scores included: age, time of disease, body mass index (BMI),
eGFR, 24 h-proteinuria at diagnosis, last 24 h-prot, hematocrit,
last serum albumin, total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides. Spearman’s correlation coefficients (rs)
were used to determine whether these estimated predictors
correlated with PCS, MCS and HAMD scores.
Patients were categorized into groups based on gender, presence
of diabetes mellitus, blood pressure status (normotensive versus
hypertensive), use of ACE inhibitor or AT1R-blocker, statins,
steroids, CsA, cyclophosphamide (yes vs. no for each drug class),
presence of hematuria and remission status (total or partial vs. no-
remission). Comparisons of PCS, MCS and HAMD scores
between the abovementioned subgroups were performed using a
two-sample t test.
Subsequent multiple linear regression modeling was used to
determine which variables that were significant in the univariate
analysis were independently associated with PCS, MCS and
HAMD score. Models for PCS, MCS and HAMD scores were
determined separately. Corresponding interaction terms were
included in the initial model. Backwards elimination was
performed, and variables (interaction terms and predictors) that
were nonsignificant at the a=0.05 level were sequentially
removed from the model. Stepwise selection was also performed
in an interactive manner, where variables with a p-value,0.10
were added to the model and variables with a p-value.0.05 were
removed. The statistical analysis was performed using SPSS 19.0
for windows. p values,0.05 were considered as statistically
significant.
Results
Population Characterization
From a group of 311 patients, 135 nephrotic-associated
glomerulopathy patients were pre-selected and an interview was
conducted in 99 glomerulopathy patients. Contact was not
possible with other 36 patients. Mean age was 36611 years old.
Ninety-nine hemodialysis patients and healthy subjects age- and
sex-matched were selected. Mean time of dialysis was 38616
months.
Complete data on clinical and demographic characteristics of
glomerulopathy patients are shown in table 1. Main histological
diagnosis was FSGS (n=49), MN (n=29), ML (n=4). Forty-three
patients were receiving steroid drugs and nineteen received
cyclosporine-based therapy. Patients undergoing steroid therapy
were receiving a mean dose of 0.2 mg/Kg/day of prednisone.
Thirty-eight patients were in total and 26 in partial remission.
Thirty-five patients had achieved no remission. Twenty-six
patients had had at least one relapse in the last three years before
study entry and the mean of relapses frequency in these patients
was 0.7/year. Only 3 patients were considered as having frequent
relapses.
Quality of Life and Depression in Glomerulopathy
Patients
Mean scores in each SF-36 domain in healthy, dialysis and
glomerulopathy patients are shown in table 2. As expected, dialysis
patients had a low score in all domains, when compared to healthy
subjects, except in mental health. Glomerulopathy patients had
low scores in all eight domains, when compared with healthy
subjects. Glomerular patients had better scores at the physical
functioning scale and worse mental health than hemodialysis
patients. All other domains were similar between these two groups.
Mental and physical health composite scores were lower in both
dialysis and glomerulopathy patients than in healthy subjects was
observed no difference between these two last groups.
Table 2. SF-36 HRQoL and HAMD comparison between glomerulopathy and hemodialysis patients and healthy subjects.
Glomerulopathy patients
(n=99)
Hemodialysis patients
(n=99) Healthy subjects (n=99)
Physical functioning scale # 70.4627.0 52.7634.1 91.4619.3
Role, physical* 37.9622.5 26.7620.9 87.0631.2
General Health* 63.2634.8 54.3624.9 81.8624.9
Bodily pain* 71.8628.4 73.7626.9 90.9621.2
Mental Health** 66.5622.6 78.3619.8 78.4618.4
Role, emotional* 57.4636.22 70.0635.4 97.3614.8
Vitality* 62.2622.1 63.1626.5 73.7619.1
Social functioning* 64.3634.0 69.6633.1 92.5619.2
Physical health composite score* 61.6621.1 56.6621.4 85.7614.9
Mental health composite score* 62.9631.9 68.1621.9 87.5614.3
Hamilton depression Rating Scaleh 8.366.9 7.065.7 5.164.1
#p,0.001 between all groups,
*p,0.001 between healthy subjects and others groups,
**p,0.01 between glomerulopathy patients and others groups,
hp=0.01 between glomerulopathy patients vs. healthy subjects.
doi:10.1371/journal.pone.0037763.t002
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37763
Quality of Life and Depression in GlomerulopathyGlomerulopathy patients were more depressed according to
HAMD than healthy subjects (48 vs. 22.4%, p=0.002) and were
similar to dialysis patients (48 vs. 43%, p=0.302). No patient was
receiving depression therapy. Overall, glomerulopathy and dialysis
patients had comparable HAMD scores (8.366.9 vs. 7.065.7,
p=0.613) and glomerulopathy patients had higher scores than
healthy patients (5.164.1, p=0.01) – see table 2. HAMD scores
presented a significant inverse correlation with mental and
physical health composite scores (r=20.402 and 20.391,
p,0.001 for both). There was no difference between patients
according to histological diagnosis (data not shown).
Factors Associated with Quality of Life and Depression in
Glomerulopathy Patients
Univariate analysis comparing the potential contributors to
PCS, MCS and HAMD score were evaluated (tables 3 and 4).
Using variables associated with each score, multiple regression
analysis demonstrated that last 24 h-proteinuria and CsA use were
associated with PCS; last 24 h-proteinuria was the only factor
associated with MCS and gender, age, last 24 h-proteinuria and
disease duration were independently associated with HAMD
scores (table 5). Proteinuria at diagnosis (rs=20.064, p=0.532
with PCS; 20.016, p=0.874 with MCS and 0.016, p=0.888 with
HAMD), eGFR (rs=0.049, p=0.613 with PCS; 0.078, p=0.322
with MCS and 0.061, p=0.496 with HAMD), mean daily
prednisone dose in the last 6 months ((rs=20.031, p=0.723 with
PCS; 0.012, p=0.822 with MCS and 0.022, p=0.896 with
HAMD) and partial or total remission were not associated with
any score evaluated.
Discussion
In this study, adult glomerulopathy patients had worse HRQoL
and high depression prevalence and severity than healthy subjects,
being comparable with patients on maintenance hemodialysis.
Moreover, we determined that actual proteinuria was associated
with HRQoL and depression.
Glomerulopathy patients have several characteristics that can
affect quality of life. Presence of severe edema, loss of renal
function, daily activities and diet restriction can potentially reduce
physical and mental aspects of quality of life. Moreover, treatment-
related adverse effects can be associated with poor quality of life.
However, only recently it has been reported that FSGS patients
with no treatment had low HRQoL scores [14], but there is no
information about the factors associated with this low HRQoL and
if reduction-proteinuria treatment has any impact on its improve-
ment. Moreover, depression was never studied in glomerulopathy
patients before.
It is known that advanced CKD patients have poor HRQoL
and severe depression diagnosis, whether they are undergoing or
not renal replacement therapy. [13,17–19] In our data, glomer-
ulopathy patients had low HRQoL and depression, comparable to
hemodialysis patients. Of eight SF-36 domains, six showed similar
scores between glomerulopathy and hemodialysis patients. Only
functional capacity was worse in hemodialysis patients; similar
findings were observed by Gipson et al. [14], when evaluating
FSGS patients. Although HRQoL in hemodialysis patients is
extensively described in literature [4], we prefer to reassess these
data with an age- and sex-matched group, due to possible regional
differences when comparing reports from developed countries.
Abdel-Kader et al. described patients with stage 4 and 5 CKD
that had comparably low HRQoL and depression [19]; however,
our cohort had a mean eGFR of 61629 mL/min/1.73 m
2 and
only six patients had stage 4 CKD. It is unlikely that low HRQoL
Table 3. Scores in subgroups based on several clinical
characteristics.
Characteristic Score Score p
Gender Male (n=46)
PCS 64.3619.7 0.225
MCS 63.7619.9 0.242
HAMD 6.364.7 0.010
Hypertension yes (n=48) no (n=51)
PCS 58.4620.3 63.2621.0 0.302
MCS 58.9619.4 61.7622.3 0.568
HAMD 9.366.5 7.966.5 0.388
Diabetes Mellitus yes (n=5) no (n=84)
PCS 56.4617.3 61.6621.0 0.589
MCS 64.9616.6 60.3621.4 0.641
HAMD 8.066.6 b8.566.2 0.883
ACE inhibitor/AT1R-blocker yes (n=68) no (n=31)
PCS 59.0619.8 63.8622.7 0.325
MCS 58.8620.6 63.4621.8 0.352
HAMD 8.366.5 8.766.3 0.844
Statin yes (n=21) no (n=78)
PCS 54.6621.4 63.1620.4 0.084
MCS 56.4621.1 62.0621.0 0.298
HAMD 8.366.3 8.665.8 0.891
Steroid therapy Yes (n=66) no (n=33)
PCS 58.0618.9 62.8622.16 0.310
MCS 58.9620.12 61.7621.8 0.562
HAMD 7.266.1 9.367.7 0.093
CsA therapy yes (n=19) no (n=80)
PCS 53.8617.8 62.2621.3 0.035
MCS 51.9619.8 62.2621.0 0.045
HAMD 10.468.9 8.166.9 0.203
Cyclophosphamide therapy yes (n=6) no (n=93)
PCS 54.7612.9 61.1621.4 0.552
MCS 65.6617.2 60.4621.4 0.634
HAMD 6.265.2 8.866.9 0.321
Hematuria yes (n=27) no (n=72)
PCS 55.2617.4 65.4621.7 0.042
MCS 56.2621.6 65.2619,7 0.071
HAMD 7.566.1 8.466.2 0.590
Remission yes (n=64) no (n=35)
PCS 61.5619.9 60.7627.2 0.906
MCS 61.7619.1 61.4627.7 0.961
HAMD 8.666.6 7.966.2 0.477
Relapses at last three years yes (n=26) no (n=73)
PCS 59.7616.8 61.7619.6 0.771
MCS 60.3618.0 62.0621.6 0.693
HAMD 8.266.2 8.466.2 0.931
PCS: SF-36 Physical composite score; MCS: SF-36 Mental composite score;
HAMD: Hamilton Depression Rating Scale; CsA: cyclosporine.
doi:10.1371/journal.pone.0037763.t003
Quality of Life and Depression in Glomerulopathyand depression burden in glomerulopathy patients be due only to a
reduced eGFR.
Only three populations with glomerulopathy have been studied
regarding HRQoL: pediatric patients with steroid-sensitive
nephrotic syndrome [20], children and adults with untreated
FSGS [14]. These studies have demonstrated a low HRQoL in
nephrotic patients. Our data includes several histological glomer-
ulopathies types. This is important in data validation and because
different features of the glomerulopathy type (remission index and
CKD evolution) can have different impacts on HRQoL.
To the best of our knowledge, depression has not been assessed
in glomerulopathy patients. In this study, glomerulopathy patients
had higher HAMD score than healthy subject and were
comparable to hemodialysis patients. In the general population,
prevalence of depression in women ranges from 5 to 9% and 2 to
3% in men [5]. It is important to distinguish between the diagnosis
of major depressive disorder and the symptoms of depression [9],
with the first being evaluated by DSM-IV [21]. HAMD is used as
an instrument to screen for depression, so it is not possible to
estimate the true prevalence of depression in the studied
population. In spite of these considerations, glomerulopathy
patients presented high HAMD scores and depression must be
assessed by a physician in this population.
It is unknown if glomerulopathy-directed treatment can
ameliorates HRQoL and depressive symptoms. An ongoing
randomized clinical trial is using HRQoL as an end-point in
FSGS patients [14]. In our sample, patients achieving partial or
total remission had comparable scores for both HRQoL and
HAMD when compared with those not achieving remission.
However, the presence of 24 h-proteinuria was independently
associated with PCS, MCS and HAMD score. These data suggest
that proteinuria reduction, even when not sufficient to be classified
as remission, can be important in order to improve HRQoL and
depression symptoms. This is important because using remission
criteria when evaluating HRQoL and depression in glomerulop-
athy patients can be inaccurate.
It is not possible to determine the pathophysiological back-
ground of the association between proteinuria and quality of life
and depression. It is possible that subjective factors such as
concerns about disease control and prognosis may interfere
directly in the assessment of HRQoL. Also, patients with higher
proteinuria levels have more dietary and physical activity
restrictions. Moreover, proteinuria is associated with inflammation
[22]. In other medical conditions [23,24], inflammation has been
associated with depression and HRQoL, suggesting that future
studies must explore this possible relationship.
Cyclosporine use was associated with low PCS. This informa-
tion is dissimilar from other data in renal transplantation [25],
where steroid-therapy is associated with low physical performance.
In our study, less than half of the patients were receiving steroid
therapy (n=43), with a mean dose of 0.2 mg/Kg/day. In
glomerulopathy, steroid therapy is generally limited to a six-
month course and steroid-resistant or dependent patients are
generally changed to CsA-based therapy. This short-term of
steroid therapy, in contrast with other clinical conditions, i.e. renal
Table 4. Significant correlations (rs) between PCS, MCS and HAMD score with clinical and laboratory data.
Physical
Composite Score p
Mental Composite
Score p HAMD Score p
Age (years) - - - - 0.200 0.034
Disease duration (months) - - - - 0.400 0.001
Last 24 h-proteinuria (mg) 20.233 0.024 20.237 0.019 0.223 0.029
Last cholesterol, total (mg/dL) - - 20.208 0.029 0.250 0.012
doi:10.1371/journal.pone.0037763.t004
Table 5. Variables independently associated with PCS, MCS and HAMD score.
Physical Composite Score
Variable B 95%CI for B p
Last 24 h-proteinuria (g/24 h) 20.182 20.223 to 20.710 0.01
CsA use 215.315 225.913 to 22.717 0.03
Mental Composite Score
Variable B 95%CI for B p
Last 24 h-proteinuria (g/24 h) 20.157 20.278 to 20.310 0.03
HAMD score
Variable B 95%CI for B p
Gender (female) 4.788 1.005 to 8.620 0.03
Age (years) 0.155 0.318 to 0.988 0.04
Disease duration (months) 0.074 0.021 to 0.128 0.01
Last 24 h-proteinuria (g/24 h) 0.050 0.018 to 0.085 0.02
doi:10.1371/journal.pone.0037763.t005
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Quality of Life and Depression in Glomerulopathytransplantation, can explain the absence of association between
steroid dose and HRQoL and HAMD scores.
In our patients, cyclosporine was used as primary choice in MN
and in steroid-resistant or dependent FSGS and ML. Generally,
these patients maintain CsA use for one year after achieving
remission, in contrast with steroid-treated patients that generally
undergo a 4 to 6 month-duration therapy. We speculate this long-
course CsA therapy can adversely affect the physical component.
Moreover, two patients receiving CsA had moderate/severe
depressive symptoms. Depression has been associated with CsA
therapy [26] and it is reversible after its withdrawal. Although no
data was available about depression diagnosis before CsA
initiation in our patients, CsA must be considered as having an
etiological role.
Disease duration and age were associated with depression. It is
known that many chronic medical conditions can impair HRQoL
and increase depression prevalence [7,27]. It is known there is a
higher prevalence of depression in older subjects [28]. As in other
chronic diseases [29,30], in this sample disease duration was also
associated with depression symptoms.
Renal function and protein excretion rate at diagnosis were not
associated with any score. The first can be explained due to high
eGFR in our sample, where 60% had only mild CKD
(eGFR.60 mL/min/1.73 m
2). The lack of association between
24 h-proteinuria at diagnosis and the association with the present
one highlights the importance of proteinuria reduction in
ameliorating HRQoL and depression.
Our study has several limitations. First, it was performed in a
developing country. The results can be different in developed
countries. In the present study, we evaluated a relatively small
number of hemodialysis patients, but our data is comparable with
those in literature [14], making this a valid control group.
Moreover control groups were age- and sex-matched. Lastly, we
cannot explain the exact mechanism of the association between
24 h-proteinuria and HRQoL and depression.
In conclusion, adult nephrotic syndrome-related glomerulopa-
thy patients had low HRQoL and high depression symptom
scores. These were comparable with those in hemodialysis
patients. Presence of proteinuria was associated with worse
HRQoL and depression. We suggest that classical cutoff points
of urine protein excretion to classify remission are not sensitive to
evaluate amelioration in HRQoL and depression symptoms.
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